# US 2016/0243219 A1 · Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0243219 A1
- Document ID: US20160243219A1
- Status: Published application
- Kind: A1
- Application number: 14/987,770
- Filed: 2016-01-05
- Published: 2016-08-25
- Earliest claimed: 2005-12-22
- Assignees: Glaxosmithkline Biologicals SA
- Applicants: Glaxosmithkline Biologicals S.A.
- Inventors: Ralph Leon BIEMANS; Nathalie Marie-Josephe GARCON; Philippe Vincent HERMAND; Jan POOLMAN; Marcelle Paulette VAN MECHELEN
- Web page: https://patentgrep.com/patent/US20160243219A1

## CPC

- A61K 39/092: {Streptococcus}
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K 47/6415: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/14: Decongestants or antiallergics
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- A61K 2039/555: {characterised by a specific combination antigen/adjuvant}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/575: {humoral response}
- A61K 2039/6031: {Proteins}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K 2039/6068: {Other bacterial proteins, e.g. OMP}
- A61K 2039/6087: {Polysaccharides; Lipopolysaccharides [LPS]}
- A61K 2039/62: {characterised by the link between antigen and carrier}
- A61K 2039/627: {characterised by the linker}
- A61K 2039/70: {Multivalent vaccine}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention discloses an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.

## Claims

### Claim 1

An immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid comprising pneumolysin detoxified by chemical means or diphtheria toxoid or CRM197 and 19F is conjugated to a second bacterial toxoid comprising diphtheria toxoid or CRM197 and further comprising conjugates of S. pneumoniae capsular saccharides 1, 4, 5, 6B, 7F, 9V, 14, 18C, 22F and 23F.

### Claim 2 (depends on 1)

The immunogenic composition of claim 1 wherein the first bacterial toxoid is a different protein to the second bacterial toxin.

### Claim 3 (depends on 1)

The immunogenic composition of claim 1 further comprising a S. pneumoniae capsular saccharide 3 conjugate.

### Claim 4 (depends on 1)

The immunogenic composition of claim 1 further comprising a S. pneumoniae capsular saccharide 6A conjugate.

### Claim 5 (depends on 1)

The immunogenic composition of claim 1 which further comprises one or more unconjugated or conjugated S. pneumoniae proteins.

### Claim 6 (depends on 5)

The immunogenic composition of claim 5 wherein said one or more S. pneumoniae proteins are selected from Poly Histidine Triad family (PhtX), Choline Binding Protein family (CbpX), CbpX truncates, LytX family, LytX truncates, CbpX truncate-LytX truncate chimeric proteins, detoxified pneumolysin (Ply), PspA, PsaA, Sp128, Sp101, Sp130, Sp125 and Sp133.

### Claim 6 (depends on 5)

The immunogenic composition of claim 5 which comprises a PhtX protein.

### Claim 7 (depends on 1)

The immunogenic composition according to claim 1 which further comprises an adjuvant.

### Claim 8 (depends on 1)

A vaccine comprising the immunogenic composition of claim 1 and a pharmaceutically acceptable excipient.

### Claim 9 (depends on 1, 8)

A process for making the vaccine according to claim 8 which comprises the step of mixing the immunogenic composition of claim 1 with a pharmaceutically acceptable excipient.

### Claim 10 (depends on 1)

A method of immunising a human host against disease caused by Streptococcus pneumoniae infection comprising administering to the host an immunoprotective dose of the immunogenic composition of claim 1.

### Claim 11 (depends on 1)

The immunogenic composition of claim 1 which comprises saccharide conjugates derived from at least all the following serotypes: 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 5, 7F wherein the GMC antibody titre induced against one or more of the vaccine components 4, 6B, 9V, 14, 18C, 19F and 23F is not significantly inferior to that induced by the PREVNAR® vaccine in human vaccinees.

### Claim 12

An immunogenic composition comprising at least four S. pneumoniae capsular saccharide conjugates containing saccharides from different S. pneumoniae serotypes wherein at least one saccharide is conjugated to PhtD or fusion protein thereof and the immunogenic composition is capable of eliciting an effective immune response against PhtD.
